Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Tumori ; 102(2): 162-7, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26917407

RESUMEN

PURPOSE: To evaluate the results of radiotherapy and the prognostic factors affecting local control in nonextremity Ewing sarcomas. METHODS: Between 1995 and 2011, 44 patients with nonextremity Ewing sarcomas were treated with radiotherapy. Tumor localizations were pelvis in 23, spine in 13, thoracic region in 5, and cranium in 3 patients. Tumor size was ≥8 cm in 56.8% of patients. Distant metastases were present in 19 of the patients at the time of diagnosis (43.1%). All patients were treated with 12 weeks of neoadjuvant chemotherapy followed by surgery and radiotherapy (45-54 Gy) or radiotherapy alone (54-64.8 Gy). Radiotherapy was applied due to microscopic residue (R1) in 5 patients after the operation and macroscopic tumor in 39 patients (macroscopic residue [R2] and nonresectable tumor). RESULTS: Median follow-up was 49 months (range 9-195). Local failures developed in 7 patients (15.9%) and local control at 5 years was 81.4%. Local recurrence was detected in 6 patients (6/38) who did not have residual tumor after RT. Progression was detected in 1 patient (1/6) who had residual tumor. All those patients with local failure experienced further distant metastases. Possible prognostic factors such as age (≤17 vs >17), tumor localization, tumor volume (≤8 cm vs >8 cm), and M status at diagnosis (0 vs 1) were not related to local control. CONCLUSIONS: Radiotherapy, either alone or adjuvant to surgery, provides local control in 80% of nonextremity Ewing sarcomas and plays an important role in treatment.


Asunto(s)
Neoplasias Óseas/radioterapia , Terapia Neoadyuvante/métodos , Sarcoma de Ewing/radioterapia , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/mortalidad , Neoplasias Óseas/patología , Neoplasias Óseas/cirugía , Quimioterapia Adyuvante , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Neoplasias Pulmonares/secundario , Masculino , Recurrencia Local de Neoplasia/prevención & control , Neoplasia Residual , Pronóstico , Dosificación Radioterapéutica , Radioterapia Adyuvante , Estudios Retrospectivos , Factores de Riesgo , Sarcoma de Ewing/tratamiento farmacológico , Sarcoma de Ewing/mortalidad , Sarcoma de Ewing/secundario , Sarcoma de Ewing/cirugía , Resultado del Tratamiento , Adulto Joven
2.
J Pediatr Hematol Oncol ; 37(6): e372-4, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26181423

RESUMEN

A 9-year-old girl diagnosed with acute myeloblastic leukemia M4 developed isolated cutaneous relapse. She was given chemotherapy including idarubicin, fludarabine, and cytarabine. Although she developed very severe pancytopenia, increase in the number and size of the lesions was seen. Total skin electron beam therapy was applied to the skin lesions for a total of 18 Gy. All lesions responded to total skin electron beam therapy, some of them completely disappeared. After resolution of the skin findings, she underwent bone marrow transplantation from her matched brother. Twenty-six months after hematopoietic stem cell transplantation she is alive without any event.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Electrones/uso terapéutico , Leucemia Mieloide Aguda/tratamiento farmacológico , Recurrencia Local de Neoplasia/radioterapia , Enfermedades de la Piel/radioterapia , Niño , Citarabina/administración & dosificación , Femenino , Humanos , Idarrubicina/administración & dosificación , Leucemia Mieloide Aguda/complicaciones , Leucemia Mieloide Aguda/patología , Recurrencia Local de Neoplasia/inducido químicamente , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Pronóstico , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/patología , Vidarabina/administración & dosificación , Vidarabina/análogos & derivados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...